These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35942672)

  • 1. Clinical studies in amyotrophic lateral sclerosis.
    Dorst J; Genge A
    Curr Opin Neurol; 2022 Oct; 35(5):686-692. PubMed ID: 35942672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.
    Sun Y; Li X; Bedlack R
    Expert Rev Neurother; 2023 Jan; 23(1):1-7. PubMed ID: 36705941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis.
    Alqallaf A; Cates DW; Render KP; Patel KA
    Ann Pharmacother; 2024 Feb; 58(2):165-173. PubMed ID: 37269231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofersen (Qalsody) for ALS.
    Med Lett Drugs Ther; 2023 Jul; 65(1681):113-114. PubMed ID: 37460141
    [No Abstract]   [Full Text] [Related]  

  • 5. Tofersen: Silver Lining or Hyperbole??
    Chawla T; Goyal V
    Ann Indian Acad Neurol; 2023; 26(5):638-640. PubMed ID: 38022476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal course of neurofilament light chain levels in amyotrophic lateral sclerosis-insights from a completed randomized controlled trial with rasagiline.
    Witzel S; Statland JM; Steinacker P; Otto M; Dorst J; Schuster J; Barohn RJ; Ludolph AC
    Eur J Neurol; 2024 Mar; 31(3):e16154. PubMed ID: 37975796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
    Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
    JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.
    Meyer T; Schumann P; Weydt P; Petri S; Koc Y; Spittel S; Bernsen S; Günther R; Weishaupt JH; Dreger M; Kolzarek F; Kettemann D; Norden J; Boentert M; Vidovic M; Meisel C; Münch C; Maier A; Körtvélyessy P
    Muscle Nerve; 2023 Jun; 67(6):515-521. PubMed ID: 36928619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
    Paganoni S; Macklin EA; Hendrix S; Berry JD; Elliott MA; Maiser S; Karam C; Caress JB; Owegi MA; Quick A; Wymer J; Goutman SA; Heitzman D; Heiman-Patterson T; Jackson CE; Quinn C; Rothstein JD; Kasarskis EJ; Katz J; Jenkins L; Ladha S; Miller TM; Scelsa SN; Vu TH; Fournier CN; Glass JD; Johnson KM; Swenson A; Goyal NA; Pattee GL; Andres PL; Babu S; Chase M; Dagostino D; Dickson SP; Ellison N; Hall M; Hendrix K; Kittle G; McGovern M; Ostrow J; Pothier L; Randall R; Shefner JM; Sherman AV; Tustison E; Vigneswaran P; Walker J; Yu H; Chan J; Wittes J; Cohen J; Klee J; Leslie K; Tanzi RE; Gilbert W; Yeramian PD; Schoenfeld D; Cudkowicz ME
    N Engl J Med; 2020 Sep; 383(10):919-930. PubMed ID: 32877582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.
    Oliveira Santos M; de Carvalho M
    Expert Rev Neurother; 2024 Jun; 24(6):549-553. PubMed ID: 38758193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).
    Bireley JD; Morren JA
    Expert Opin Investig Drugs; 2023; 32(8):677-683. PubMed ID: 37642362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing pharmacologic treatment for ALS to improve outcomes and quality of life.
    Lynch K
    Am J Manag Care; 2023 Jun; 29(7 Suppl):S112-S119. PubMed ID: 37433092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Edaravone: A New Treatment for ALS].
    Yamashita T; Abe K
    Brain Nerve; 2019 Nov; 71(11):1245-1251. PubMed ID: 31722310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials in amyotrophic lateral sclerosis.
    McDermott CJ
    Curr Opin Neurol; 2019 Oct; 32(5):758-763. PubMed ID: 31335338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
    Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
    Muscle Nerve; 2022 Nov; 66(5):583-592. PubMed ID: 36054038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.
    Singh P; Belliveau P; Towle J; Neculau AE; Dima L
    Am J Ther; 2024 May-Jun 01; 31(3):e258-e267. PubMed ID: 38691665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.
    Park JM; Kim SY; Park D; Park JS
    Neurol Sci; 2020 Jan; 41(1):119-123. PubMed ID: 31471712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.